Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Oct 29, 2026
First-half results and revised FY2026 outlook
NYSE: $TAKBiopharmaceuticals · Specialty medicines
TAK Stock Hub: Takeda News, New Medicine Launches and Pipeline Catalysts
Takeda is funding a new launch cycle from an established global medicines business. Revenue for the six months ended September 30, 2026 was JPY 2,407.0 billion, up 8.4% at actual exchange rates but down 1.0% at constant exchange rates. MIMRYLO is available in the United States, while the U.S. ORZEYFUL launch remains conditional on DEA scheduling and zasocitinib remains under review. Adjusted net debt to adjusted EBITDA was 2.5 times at September 30.
Full research report · PDF
Takeda Pharmaceutical Company Limited research · November 1, 2026
20 pages covering the business, financial position, catalysts, risks, scenarios and sources. A dated snapshot for personal use; redistribution prohibited.
Next catalyst
early November 2026 · ORZEYFUL U.S. commercial launch
company target; conditional on DEA scheduling Announcement and terms
TAK stock at a glance
Calculated equity value
66.81
USD billion · 2026-10-30 · 20.91 × 2 × (1,602,218,559 issued ordinary shares minus 4,769,662 treasury shares at September 30, 2026)
Financial referenceCash and cash equivalents
418.53
JPY billion · 2026-09-30 · IFRS balance-sheet cash; includes amounts subject to company adjustments for temporary third-party cash
Financial referenceBonds and loans
4,575.60
JPY billion · 2026-09-30 · Carrying value; excludes other liability categories such as leases
Financial referenceAdjusted net debt / adjusted EBITDA
2.50
times · 2026-09-30 · Company-defined non-IFRS, trailing twelve-month EBITDA
Financial referenceNon-treasury ordinary shares
1,597,448,897
ordinary shares · 2026-09-30 · 1,602,218,559 issued less 4,769,662 treasury; full-company ADS equivalent 3,194,897,794
Financial referenceWhere Takeda Pharmaceutical Company Limited stands now
Takeda has moved two leading programs beyond the clinical-development stage: MIMRYLO launched in the United States in August, and ORZEYFUL became available in Japan and China in October. U.S. availability for ORZEYFUL remained subject to DEA scheduling in the October 29 update, with early-November timing expected. Zasocitinib adds a separate first-quarter 2027 FDA review window.
The current portfolio continues to supply the financial base for that transition. First-half reported operating profit was JPY 406.7 billion and operating cash flow was JPY 431.9 billion. Currency supported the reported revenue comparison, while substantial debt, launch costs and later-stage research create competing demands on capital.
The main risk is a gap between investment and replacement earnings: launch uptake or clinical progress could be slower than the spending committed to them, while mature products face competition and loss of exclusivity. Debt, dividends and an expanding non-treasury share base make the return retained per share important alongside scientific progress.
The constructive case
Established brands retain patients, launches gain access and prescribing, pipeline evidence remains useful and operating cash supports investment and stronger financial flexibility.
The cautious case
Launch uptake and clinical outcomes lag investment, mature-product pressure persists, currency support reverses and financing/distributions constrain flexibility.
Read also: BioCryst $BCRX $IONS $TAK $NTLA: HAE Treatment Choices →
Latest Takeda Pharmaceutical Company Limited news
Oct 29, 2026
First-half results and revised FY2026 outlook
Revenue JPY 2,407.0bn; actual-currency growth 8.4% versus constant-currency decline 1.0%. Full-year outlook revised; new launches and pipeline progressed.
Oct 23, 2026
Arcotatug tavatecan meets Phase 3 dual primary endpoints
G-HOPE-001 met overall-survival and progression-free-survival endpoints in the specified previously treated CLDN18.2-positive gastric/GEJ population. Findings support planned Japan filing and further development.
Oct 19, 2026
ENTYVIO VERDICT treatment-target results
The study compared targeting disease clearance with targeting symptomatic remission in ulcerative colitis, reporting longer time to first disease-related complication for the disease-clearance strategy.
Oct 15, 2026
ORZEYFUL becomes available in Japan and China
International launch achieved. U.S. launch remained conditional on DEA scheduling; later October results expected early-November availability.
Oct 14, 2026
TAK-881 IgGNITE results presented
Investigational facilitated SCIG 20% met its primary pharmacokinetic comparability endpoint versus HYQVIA in participants aged 16 and older.
Sep 30, 2026
Zasocitinib head-to-head Phase 3 results
LATITUDE Atlas week-16 PASI100 was 36.5% versus 13.9% with deucravacitinib in the randomized study; regulatory review continues.
TAK stock catalysts
- early November 2026 · ORZEYFUL U.S. commercial launchcompany target; conditional on DEA scheduling
- 2026-12-11 · Capital Markets Day, Tokyoannounced investor event
- Q1 calendar 2027 · Zasocitinib FDA target actionregulatory target window; NDA under Priority Review
- Q1 calendar 2027 · Pediatric intravenous ENTYVIO FDA target actionregulatory target window; sBLA under review
- 2027-03-31 · FY2026 year endfinancial reporting-period end, not an earnings release date
Three medicines at different commercial stages
| Medicine | Position at the October 29 update | What comes next |
|---|---|---|
| ORZEYFUL | Approved in the U.S., Japan and China; available in Japan and China. | U.S. availability expected in early November, conditional on DEA scheduling. |
| MIMRYLO | FDA approval and U.S. launch achieved in August 2026. | Access, prescribing and the development of a durable patient franchise. |
| Zasocitinib | Investigational medicine under FDA Priority Review and European review. | FDA target action period in the first quarter of calendar 2027. |
The financial base and the claims on it
| Measure | Amount | Period and basis |
|---|---|---|
| Revenue | JPY 2,407.0 billion | Six months ended September 30, 2026; IFRS. |
| Operating cash flow | JPY 431.9 billion | Six months ended September 30, 2026. |
| Bonds and loans | JPY 4,575.6 billion | September 30, 2026; carrying value. |
| Adjusted net debt / adjusted EBITDA | 2.5 times | September 30, 2026; company-defined non-IFRS measure. |
The leverage ratio improved while adjusted net debt increased. The ratio reflects earnings capacity as well as debt, and the company’s cash-availability adjustments remain relevant. Financial statements · Definitions and reconciliations
Merlintrader Health Score · $TAK
3.60out of 5
Assessed November 1, 2026. An editorial assessment of financial and operating resilience over twelve to eighteen months; no price target or recommendation is implied.
Red flags
- The October 29 U.S. ORZEYFUL launch plan remained conditional on DEA scheduling.
- First-half revenue declined 1.0% at constant exchange rates despite reported yen growth of 8.4%.
- Adjusted net debt increased between March and September even as the adjusted leverage ratio improved.
- The balance-sheet cash figure includes amounts subject to company adjustments for temporary third-party cash.
- New launches require access, prescribing and continued use before reaching a mature contribution.
- Partner royalties and territory-specific rights affect the economics retained by Takeda.
- Issued shares increased and treasury shares declined during the half-year.
TAK Stock FAQ: Takeda Pharmaceutical Company Limited Questions Answered
What does one TAK ADS represent?
Half an ordinary share; two ADSs equal one ordinary. Company financials are in JPY and ordinary-share EPS, while NYSE ADS price is in USD.
Has ORZEYFUL launched in the United States?
October 29 results retained DEA scheduling as a condition, with early-November U.S. availability expected. Japan and China availability began October 15.
What are the nearest dated catalysts?
December 11 Capital Markets Day, the first quarter of calendar 2027 FDA action windows for zasocitinib and pediatric ENTYVIO, and the nearer conditional ORZEYFUL U.S. launch plan.
Why do reported and Core earnings differ?
Core measures adjust specified items such as product-related amortization and impairment; use reconciliations alongside IFRS results and cash flow.
Is Takeda dependent on one new medicine?
The group has an established diversified portfolio, but mature-product pressure, several launches, research, debt and distributions create simultaneous demands.
Primary sources and market references
- Takeda's first-half announcement
- Takeda's annual business description
- Takeda's stock and ADS information
- September share-count disclosure
- October 30 historical closing prices
- First-half Core reconciliation and financial review
- Revised forecast in the quarterly financial report
- Takeda's VERDICT announcement
- Pediatric application announcement
- October 14 IgGNITE results
- TAKHZYRO product information
- FDA announcement on ORZEYFUL
- FDA approval letter
- FDA approval announcement
- Takeda's approval release
- MIMRYLO prescribing information
- Protagonist's second-quarter contractual disclosure
- Takeda's September regulatory announcement
- LATITUDE Atlas data announcement
- Arrowhead's description of the partnered program
- Japanese government trial registration
- Takeda's ELRiSE MDS study description
- October G-HOPE-001 announcement
- October results presentation
- International launch announcement and U.S. plan
- Takeda's dated investor-event announcement
Disclaimer. Published by Merlintrader for educational and informational purposes only. This content does not constitute investment advice or a recommendation to buy, sell or hold securities. Verify figures against the dated primary disclosures. Investors can lose part or all of their capital.
Pharmaceutical companies face clinical, regulatory, safety, manufacturing, intellectual-property, reimbursement, pricing and competitive risks. A new approval may require substantial commercial investment before generating mature revenue. Partner obligations, debt, share issuance and foreign-exchange movements can affect the value retained by shareholders, and securities may lose substantial or all of their value.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information: disclaimer and terms of use and privacy.
